8 terminated. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow cyclopia sequence: new trials by email Literature Review of cyclopia sequence trials Research Report on cyclopia sequence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maimonides Minocycline in Stroke Study Minocycline - Stroke, Acute, Ischemic Stroke | Phase 2 / Phase 3 | Terminated | Maimonides Medical Center | 2 | 2023-11-01 | 2025-12-17 |
| Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease Minocycline - Mycobacterium Avium Complex Pulmonary Disease | Phase 2 | Terminated | Radboud University Medical Center | 12 | 2023-05-08 | 2025-06-29 |
| Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer Minocycline, Placebo, Questionnaires - Head And Neck Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 30 | 2014-05-06 | 2022-10-20 |
| The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression Minocycline, Placebo, Ketamine - Depressive Disorder | Phase 2 | Terminated | Janssen Research & Development, LLC | 29 | 2013-06-01 | 2015-06-30 |
| Symptom Burden in Head and Neck Cancer Placebo, Armodafinil, Minocycline - Head And Neck Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2013-03-01 | 2015-02-10 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients Topical Minocycline Foam FXFM244 - Rosacea | Phase 2 | Terminated | Vyne Therapeutics Inc. | 21 | 2010-06-01 | 2015-08-26 |
| Neuroprotection and Repair in Optic Neuritis Minocycline - Multiple Sclerosis, Optic Neuritis | Phase 2 | Terminated | University of Calgary | 6 | 2010-02-01 | 2013-01-23 |
| Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] Minocycline, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Terminated | Merck KGaA, Darmstadt, Germany | 305 | 2006-02-01 | 2013-12-27 |
Head and Neck Neoplasms (2) · Carcinoma (1) · Depression (1) · Depressive Disorder (1) · Depressive Disorder, Major (1) · Hemorrhagic Stroke (1) · Ischemic Stroke (1) · Laryngeal Diseases (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Optic Neuritis (1) · Rosacea (1) · Stroke (1)
Nervous System Diseases (3) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Behavior (1) · Behavioral Symptoms (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Cranial Nerve Diseases (1)
Minocycline (7) · Bupropion (1) · Ketamine (1) · Modafinil (1) · Sugars (1) · Surveys and Questionnaires (1)
M.D. Anderson Cancer Center (2) · Janssen Research & Development, LLC (1) · Maimonides Medical Center (1) · Merck KGaA, Darmstadt, Germany (1) · Radboud University Medical Center (1) · University of Calgary (1) · Vyne Therapeutics Inc. (1)
United States (3) · Netherlands (2) · Belgium (1) · Denmark (1) · France (1) · Israel (1) · Spain (1)
David I. Rosenthal, MD, MA, BA (1) · Fiona Costello, Dr. (1) · Juan P. Cata, MD (1) · Luanne Metz, Dr. (1) · Wouter Hoefsloot, MSc, PhD (1)
2005 (1), R01CA026582 (1)